Key result
Baroreflex activation therapy safely improves symptoms, exercise capacity, NT-proBNP, and quality of life in HFrEF.
Why the study?
Does baroreflex activation therapy improve symptomatic outcomes in patients with heart failure with reduced ejection fraction?
RCT
Does baroreflex activation therapy improve symptomatic outcomes in patients with heart failure with reduced ejection fraction?
Baroreflex activation therapy improves symptomatic outcomes in HFrEF patients and is FDA-approved for those remaining symptomatic on GDMT who are ineligible for CRT.
A randomized, controlled trial of baroreflex activation therapy (BAT) in patients with heart failure and reduced ejection fraction demonstrated that BAT was safe and significantly improved patient-centered symptomatic outcomes, increasing exercise capacity, improving quality of life, decreasing n-terminal pro B-type natriuretic peptide (NT-proBNP), and improving functional class. BAT was approved by the FDA for improvement of symptoms of heart failure for patients who remain symptomatic despite treatment with guideline-directed management, are New York Heart Association Class III or Class II (with a recent history of Class III), have a left ventricular ejection fraction ≤ 35%, an NT-proBNP < 1600 pg/mL and excluding patients indicated for cardiac resynchronization therapy.
No takes yet. Share an insight, caveat, or question.
Ruddy et al. (2026) conducted an RCT in Heart failure with reduced ejection fraction. Baroreflex activation therapy (BAT) was evaluated on Patient-centered symptomatic outcomes, exercise capacity, quality of life, NT-proBNP, and functional class. Baroreflex activation therapy safely and significantly improved patient-centered symptomatic outcomes, exercise capacity, quality of life, NT-proBNP, and functional class in patients with HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: